ADC Therapeutics S.A. (ADCT) — Analyst outlook / Analyst consensus target is. Based on 12 analyst ratings, the consensus is bullish — 7 Buy, 4 Hold, 1 Sell.
The consensus price target is $7.50 (low: $5.00, high: $10.00), representing an upside of 94.3% from the current price $3.86.
Analysts estimate Earnings Per Share (EPS) of $-1.69 and revenue of $0.07B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.62 vs est $-1.69 (beat +4.1%). 2025: actual $-1.12 vs est $-1.41 (beat +20.3%). Analyst accuracy: 85%.
ADCT Stock — 12-Month Price Forecast
$7.50
▲ +94.30% Upside
Average Price Target
Based on 12 Wall Street analysts offering 12-month price targets for ADC Therapeutics S.A., the average price target is $7.50, with a high forecast of $10.00, and a low forecast of $5.00.
The average price target represents a +94.30% change from the last price of $3.86.
Highest Price Target
$10.00
Average Price Target
$7.50
Lowest Price Target
$5.00
ADCT Analyst Ratings
Buy
Based on 12 analysts giving stock ratings to ADC Therapeutics S.A. in the past 3 months
EPS Estimates — ADCT
85%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.62
vs Est –$1.69
▲ 4.3% off
2025
Actual –$1.12
vs Est –$1.41
▲ 25.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ADCT
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.069B
vs Est $0.073B
▼ 4.9% off
2025
Actual $0.081B
vs Est $0.081B
▲ 1.0% off
Revenue Trend
Moderate revenue growth trend. Analysts expect stable revenue going forward.
